Get the Stockscreener App
29.62
2.95%
-0.90
Pre-market:
29.66
0.04
+0.14%
Hims Hers Health Inc stock is traded at $29.62, with a volume of 14.13M.
It is down -2.95% in the last 24 hours and down -14.89% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$30.52
Open:
$30.14
24h Volume:
14.13M
Relative Volume:
0.75
Market Cap:
$6.74B
Revenue:
$1.78B
Net Income/Loss:
$164.40M
P/E Ratio:
42.93
EPS:
0.69
Net Cash Flow:
$236.51M
1W Performance:
-5.61%
1M Performance:
-14.89%
6M Performance:
-48.95%
1Y Performance:
-4.11%
1-Day Range:
$29.40
$30.99
1-Week Range:
$27.96
$31.30
52-Week Range:
$23.97
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
29.62 | 6.95B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
124.05 | 54.82B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.29 | 50.36B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.46 | 46.00B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.81 | 36.32B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
468.94 | 20.33B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Hims & Hers Health: The Reset Nobody Expected (NYSE:HIMS) - Seeking Alpha
Y Intercept Hong Kong Ltd Grows Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
A Profitable Company Under Siege: The Curious Case of Hims & Hers - AD HOC NEWS
End Of Novo Nordisk GLP-1 Deal Could Be A Game Changer For Hims & Hers Health (HIMS) - Sahm
Peering Into Hims & Hers Health Inc's Recent Short Interest - Sahm
Lobbying Update: $330,000 of HIMS & HERS HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Healthcare Stocks To Keep An Eye OnJanuary 23rd - MarketBeat
Steadview Capital Management LLC Purchases 311,845 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
TipRanksXAI Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Cuts Target Price to $31 - Futubull
183,304 Shares in Hims & Hers Health, Inc. $HIMS Acquired by Emerald Mutual Fund Advisers Trust - MarketBeat
How (HIMS) Movements Inform Risk Allocation Models - Stock Traders Daily
What are the hidden costs of weight loss for Americans? - leader-call.com
Healthcare Stocks To ConsiderJanuary 22nd - MarketBeat
HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling? - Yahoo Finance
Why Hims & Hers Stock Slipped Today - AOL.com
QRG Capital Management Inc. Decreases Stock Holdings in Hims & Hers Health, Inc. $HIMS - MarketBeat
Emerald Advisers LLC Acquires New Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
Okupe, CFO of Hims & Hers, sells $275k in HIMS stock By Investing.com - Investing.com South Africa
Okupe, CFO of Hims & Hers, sells $275k in HIMS stock - Investing.com
Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 9,067 Shares of Stock - MarketBeat
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Hims & Hers Health (NYSE:HIMS) Stock Price Down 6.2%Here's Why - MarketBeat
Hims & Hers Health Inc. Stock (HIMS) Opinions on Recent Price Decline - Quiver Quantitative
Best Healthcare Stocks To ConsiderJanuary 5th - MarketBeat
Hims & Hers Health (NYSE:HIMS) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Top 3 Health Care Stocks That Could Blast Off This Month - Benzinga
Hims & Hers Health Stock Outlook: Modeling a 95% Upside Case - TIKR.com
Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets - MSN
Hims And Hers Wegovy Talks Could Reshape Growth And Subscriber Economics - simplywall.st
2 Top Stocks to Double Up On Right Now - Yahoo Finance
2 Top Stocks to Double Up On Right Now - The Motley Fool
Why Hims & Hers Health (HIMS) Stock Is Down Today - Finviz
Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Hims & Hers Expands Platform-Led Access to Digital Healthcare - The Globe and Mail
Published on: 2026-01-18 05:20:30 - baoquankhu1.vn
Portfolio Recap: Does SKLZ stock benefit from AI growthJuly 2025 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Market Review: Is Hims Hers Health Inc a top pick in the sectorMarket Risk Report & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Hims GLP-1 Weight Loss Guide 2026: Injectable and Oral Treatment Options for Men (Semaglutide and Tirzepatide) - Newswire.com
Hims & Hers And HIMZ: Short‑Term Pain From Novo, Long‑Term Opportunity Still Bright (HIMS) - Seeking Alpha
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now? - Yahoo Finance
Hims & Hers Shares Face Heightened Volatility on Key Expiry Date - AD HOC NEWS
Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s - Sherwood News
Is Hims & Hers (HIMS) Using Zava to Balance GLP-1 Uncertainty with Broader Platform Ambitions? - Sahm
Promising Healthcare Stocks To Follow NowJanuary 14th - MarketBeat
BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS) - Insider Monkey
Hims & Hers: Growth Catalysts Or Margin Trap (NYSE:HIMS) - Seeking Alpha
A Look At Hims & Hers Health (HIMS) Valuation As Amazon Targets The Weight Loss Segment - Sahm
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - MSN
OMCL vs. HIMS: Which Stock Is the Better Value Option? - Yahoo Finance
Belvedere Trading LLC Sells 35,095 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill - Yahoo Finance
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):